TY - JOUR
T1 - Muscle Channelopathies
AU - Trivedi, Jaya R.
N1 - Funding Information:
RELATIONSHIP DISCLOSURE: Dr Trivedi has received personal compensation in the range of $500 to $4999 for serving on a scientific advisory or data safety monitoring board for argenx. The institution of Dr Trivedi has received research support from the National Institutes of Health (NIH).
Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - PURPOSE OF REVIEW This article describes the clinical features, diagnosis, pathophysiology, and management of nondystrophic myotonia and periodic paralysis. RECENT FINDINGS An increasing awareness exists about the genotype-phenotype overlap in skeletal muscle channelopathies, and thus genetic testing is needed to make a definitive diagnosis. Electrodiagnostic testing in channelopathies is highly specialized with significant overlap in various mutation subtypes. Randomized clinical trials have now been conducted in these disorders with expanded treatment options for patients with muscle channelopathies. SUMMARY Skeletal muscle channelopathies are rare heterogeneous conditions characterized by lifelong symptoms that require a comprehensive management plan that includes pharmacologic and nonpharmacologic interventions. The significant variability in biophysical features of various mutations, coupled with the difficulties of performing clinical trials in rare diseases, makes it challenging to design and implement treatment trials for muscle channelopathies.
AB - PURPOSE OF REVIEW This article describes the clinical features, diagnosis, pathophysiology, and management of nondystrophic myotonia and periodic paralysis. RECENT FINDINGS An increasing awareness exists about the genotype-phenotype overlap in skeletal muscle channelopathies, and thus genetic testing is needed to make a definitive diagnosis. Electrodiagnostic testing in channelopathies is highly specialized with significant overlap in various mutation subtypes. Randomized clinical trials have now been conducted in these disorders with expanded treatment options for patients with muscle channelopathies. SUMMARY Skeletal muscle channelopathies are rare heterogeneous conditions characterized by lifelong symptoms that require a comprehensive management plan that includes pharmacologic and nonpharmacologic interventions. The significant variability in biophysical features of various mutations, coupled with the difficulties of performing clinical trials in rare diseases, makes it challenging to design and implement treatment trials for muscle channelopathies.
UR - http://www.scopus.com/inward/record.url?scp=85144588789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144588789&partnerID=8YFLogxK
U2 - 10.1212/CON.0000000000001183
DO - 10.1212/CON.0000000000001183
M3 - Article
C2 - 36537980
AN - SCOPUS:85144588789
SN - 1080-2371
VL - 28
SP - 1778
EP - 1799
JO - CONTINUUM Lifelong Learning in Neurology
JF - CONTINUUM Lifelong Learning in Neurology
IS - 6
ER -